suggested that clinical trials testing the efficacy of FGFR inhibitors in the adjuvant setting to prevent recurrence and death are warranted because FGFR2 mutations are associated with poor outcomes in EEC [43]. Here, FGFR2 is linked to exstrophy-epispadias complex.